RAPT Therapeutics, Inc. (NASDAQ:RAPT) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 1,160,000 shares, a growth of 27.6% from the March 31st total of 908,900 shares. Based on an average daily trading volume, of 143,400 shares, the short-interest ratio is presently 8.1 days. Approximately 7.2% of the company’s shares are short sold.

Shares of NASDAQ RAPT traded down $0.13 during trading hours on Tuesday, reaching $21.91. The stock had a trading volume of 91,223 shares, compared to its average volume of 146,785. The firm has a market cap of $544.86 million, a price-to-earnings ratio of -8.63 and a beta of -0.03. The business’s fifty day moving average price is $21.89 and its two-hundred day moving average price is $22.73. RAPT Therapeutics has a 52-week low of $14.09 and a 52-week high of $41.86.

RAPT Therapeutics (NASDAQ:RAPT) last issued its quarterly earnings results on Thursday, March 11th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.06. The business had revenue of $1.30 million for the quarter, compared to analyst estimates of $2.05 million. As a group, equities research analysts anticipate that RAPT Therapeutics will post -2.18 EPS for the current year.

Separately, HC Wainwright boosted their target price on RAPT Therapeutics from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, March 18th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. RAPT Therapeutics currently has a consensus rating of “Buy” and an average target price of $38.40.

Several hedge funds have recently modified their holdings of RAPT. Nuveen Asset Management LLC grew its holdings in shares of RAPT Therapeutics by 1.1% during the fourth quarter. Nuveen Asset Management LLC now owns 43,882 shares of the company’s stock valued at $867,000 after buying an additional 483 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of RAPT Therapeutics by 1.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 66,345 shares of the company’s stock valued at $1,311,000 after buying an additional 948 shares during the last quarter. Rhumbline Advisers grew its holdings in shares of RAPT Therapeutics by 12.4% during the fourth quarter. Rhumbline Advisers now owns 11,200 shares of the company’s stock valued at $221,000 after buying an additional 1,233 shares during the last quarter. Northern Trust Corp raised its stake in shares of RAPT Therapeutics by 1.6% during the 4th quarter. Northern Trust Corp now owns 150,793 shares of the company’s stock worth $2,978,000 after buying an additional 2,348 shares during the period. Finally, Citigroup Inc. raised its stake in shares of RAPT Therapeutics by 565.7% during the 4th quarter. Citigroup Inc. now owns 3,508 shares of the company’s stock worth $69,000 after buying an additional 2,981 shares during the period. 65.02% of the stock is currently owned by institutional investors and hedge funds.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer.

Featured Article: Blockchain

Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.